|Bid||37.36 x 900|
|Ask||37.37 x 1200|
|Day's Range||37.29 - 37.54|
|52 Week Range||32.32 - 39.43|
|PE Ratio (TTM)||10.38|
|Earnings Date||Jul 31, 2018|
|Forward Dividend & Yield||1.36 (3.66%)|
|1y Target Est||39.86|
Pfizer Inc. (PFE) and Spark Therapeutics (ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in the usual care setting. The factor IX prophylaxis efficacy data obtained in the lead-in study will serve as the within-subject control group for those patients that enroll into the next part of the Phase 3 study, which will evaluate the investigational gene therapy fidanacogene elaparvovec for the treatment of hemophilia B. The interventional portion of this pivotal Phase 3 study will enroll patients who have completed at least six months in the lead-in study.
The drugmaker's second reorganization in four years signals where the company is headed. But it doesn't solve its most serious problem.
FDA approves Pfizer's (PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.
Three Dow stocks could be on the hot seat, but one looks like a sure shot to be shown the door next year.
A small Colorado drugmaker recently raised the price for a spray form of sleep aid Ambien by as much as 843%, the latest example of how some firms are increasing prices despite mounting pressure. The median price increase is 8%, but some specific increases have been far greater. Aytu BioScience Inc. raised the list price of a 7.7 milliliter bottle of its sleep aid Zolpimist to $659 from $69.88, while increasing the price of a 4.5 milliliter bottle by 747% to $329.50, according to RELX PLC’s Elsevier Gold Standard Drug Database.
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide), following FDA Priority Review designation, based on results from the Phase 3 PROSPER trial. The FDA action broadens the indication for XTANDI to men with castration-resistant prostate cancer (CRPC), now including men with non-metastatic CRPC. This approval makes XTANDI the first and only oral medication FDA-approved for both non-metastatic and metastatic CRPC.
First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC TOKYO and NEW YORK , July 13, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa ...
Did you ever copy from the smart kid in class and then score straight A’s? Well, now you can replicate this savvy move with top investor trades — and make some money while you’re at it!
News of positive clinical data for its Alzheimer’s study lifted the entire biotechnology sector. Oddly enough, markets largely ignored pharmaceutical stocks, choosing instead to invest in the riskier biotech sector. The following are Big Pharma stocks that should be on the radar of most investors.
Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.
The index enjoyed a strong week of gains, boosted by expectations of a strong second quarter earnings season.
When Ian Read decided to hoist the price of 100 products earlier this month, the Pfizer chief executive was unprepared for the fallout. Shortly after, he received a telephone call from Alex Azar, the health secretary, who warned him the President was not bluffing. “Alex conveyed that Mr Trump was very angry with Pfizer,” said one person briefed on the call.
Celgene Corporation (NASDAQ:CELG) stock looks attractive here, for a number of reasons. Celgene stock has sold off, losing about 43% of its value. Celgene touched a four-year low in May before a recent rebound. The decline leaves Celgene looking awfully cheap, at a little over 8.3x 2019 consensus EPS estimates.
Pfizer (PFE) is re-organizing its business into three business segments, effective 2019. It is separating its consumer healthcare business into a standalone unit.
The " Fast Money " traders shared their first moves for the market open. Tim Seymour is a buyer of Canopy Growth CGC-CA Karen Finerman is a buyer of Delta DAL Steve Grasso is a buyer of General Electric ...
Gene therapy continues to be in focus with the recent spate of deals and acquisitions. We highlight three stocks, which have promising candidates in their pipeline.
NEW YORK, NY / ACCESSWIRE / July 12, 2018 / Shares of Achieve Life Sciences exploded on Wednesday after the company announced the advancement of the Cytisine Development Program after its meeting with ...
Less than 48 hours after Donald Trump took to Twitter to say the company “should be ashamed” of raising prices on 100 products, the drugmaker demurred and said it would defer the increases. also followed a series of thinly veiled warnings from Alex Azar, the health secretary, who said its decision to raise prices this month would “be remembered for creating a tipping point in US drug pricing policy”. The company said it would defer the increases until the end of the year or until Mr Trump implements his “blueprint to strengthen the healthcare system” — a complex string of measures announced in May, aimed at lowering drug prices.
Pfizer Inc. is organizing itself into three different businesses as it continues to mull the future of its over-the-counter medicines unit. The drugmaker said Wednesday it will have an innovative medicines business, a consumer health-care division, which includes the company’s over-the-counter drugs, and an established medicines division, which would have brands such as Viagra and Lipitor. The company said the innovative medicines and consumer health-care divisions will make up around 75% of Pfizer’s revenue.
FT premium subscribers can click here to receive Due Diligence every day by email. One scoop to start: Tiger Global, the $22bn US investment manager, has taken a stake of more than $1bn in Japan’s SoftBank, saying it believes the stock is “meaningfully undervalued”. A long-simmering takeover battle for Sky, the European pay-TV group that reaches 23m customers across the continent, erupted in spectacular fashion on Wednesday.
President Donald Trump succeeded in convincing Pfizer Inc. to hold off on price increases it had planned for this month. In the first 10 days of July, at least ten other drugmakers and biotechnology companies raised prices on at least 20 brand-name medicines, a review of pricing data from Rx Savings Solutions and Bloomberg Intelligence shows. Celgene Corp. raised the price of blockbuster cancer drug Revlimid by 5 percent to $695.48 a capsule, according to data compiled by Bloomberg Intelligence and First Databank.
Activist investors are well on their way to taking over a large chunk of corporate America and Europe seems to be their next frontier. For sure, the likely targets are-and continue to be-sprawling corporates like Nestle, Deutsche Bank and Thyssenkrupp. Well, that happened Wednesday as Elliott Management, one of the most influential activist hedge funds, has gained control of one of Europe's most iconic soccer clubs Associazione Calcio Milan SpA, better known as AC Milan.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks from the floor of the New York Stock Exchange.